<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="correction" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id><journal-title-group><journal-title>BMC Cancer</journal-title></journal-title-group><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40410766</article-id><article-id pub-id-type="pmc">PMC12100949</article-id><article-id pub-id-type="publisher-id">14339</article-id><article-id pub-id-type="doi">10.1186/s12885-025-14339-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Correction</subject></subj-group></article-categories><title-group><article-title>Correction: Hospital factors and metastatic surgery in colorectal cancer patients, a population-based cohort study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Ljunggren</surname><given-names>Malin</given-names></name><address><email>malin.ljunggren@ki.se</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Dietrich</surname><given-names>Caroline E.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Rosander</surname><given-names>Emma</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Palmer</surname><given-names>Gabriella</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Glimelius</surname><given-names>Bengt</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Martling</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Nordenvall</surname><given-names>Caroline</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00m8d6786</institution-id><institution-id institution-id-type="GRID">grid.24381.3c</institution-id><institution-id institution-id-type="ISNI">0000 0000 9241 5705</institution-id><institution>Department of Molecular Medicine and Surgery, </institution><institution>Karolinska Institutet, Colorectal Surgery Unit, Karolinska University Hospital, </institution></institution-wrap>Anna Stecks&#x000e9;ns Gata 30 A D2:05, Solna Stockholm, 171 76 Sweden </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00m8d6786</institution-id><institution-id institution-id-type="GRID">grid.24381.3c</institution-id><institution-id institution-id-type="ISNI">0000 0000 9241 5705</institution-id><institution>Medical Unit of Trauma, Emergency Surgery and Orthopaedics, </institution><institution>Karolinska University Hospital, </institution></institution-wrap>Stockholm, Sweden </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/056d84691</institution-id><institution-id institution-id-type="GRID">grid.4714.6</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0626</institution-id><institution>Clinical Epidemiology Division, Department of Medicine, </institution><institution>Karolinska Institutet, </institution></institution-wrap>Stockholm, Sweden </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00hm9kt34</institution-id><institution-id institution-id-type="GRID">grid.412154.7</institution-id><institution-id institution-id-type="ISNI">0000 0004 0636 5158</institution-id><institution>Department of Surgery and Urology, </institution><institution>Danderyd Hospital, </institution></institution-wrap>Stockholm, Sweden </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00m8d6786</institution-id><institution-id institution-id-type="GRID">grid.24381.3c</institution-id><institution-id institution-id-type="ISNI">0000 0000 9241 5705</institution-id><institution>Department of Pelvic Cancer, GI Oncology and Colorectal Surgery Unit, </institution><institution>Karolinska University Hospital, </institution></institution-wrap>Stockholm, Sweden </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/048a87296</institution-id><institution-id institution-id-type="GRID">grid.8993.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9457</institution-id><institution>Department of Immunology, Genetics and Pathology, </institution><institution>Uppsala University, </institution></institution-wrap>Uppsala, Sweden </aff></contrib-group><pub-date pub-type="epub"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>25</volume><elocation-id>929</elocation-id><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><related-article related-article-type="corrected-article" ext-link-type="doi" xlink:href="10.1186/s12885-022-10005-8" id="d33e54"/><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p id="Par1">
<bold>Correction: BMC Cancer 22, 907 (2022)</bold>
</p><p id="Par2">
<bold>https://doi.org/10.1186/s12885-022&#x02013;10005-8</bold>
</p><p id="Par3">Following publication of the original article [<xref ref-type="bibr" rid="CR1">1</xref>], the authors identified an error in the original code to calculate the hospital volume quartiles. The error led to the effect that the quartiles were calculated based on the distribution of annual hospital volumes across the study period instead of calculations year by year. This led to ubiquitous but very slight changes throughout the manuscript. The effect size of the main results is essentially unchanged, and the statistical significance of the results is, thus, untouched. Two changes are noted. Firstly, the annual volumes of incident mCRC patients at hospitals in the 1st, 2nd, 3rd, and 4th quartiles now overlap with 1&#x02013;26, 18&#x02013;37, 28&#x02013;53, 39&#x02013;103 patients per year, respectively (previously 1&#x02013;20, 21&#x02013;31,32&#x02013;46, 47&#x02013;103). Secondly, in the patient characteristics table (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>) the annual hospital volume quartiles had significantly different proportions regarding the variable &#x0201c;year of diagnosis&#x0201d; (2009&#x02013;2012/ 2013&#x02013;2016). The p-value indicate that the proportion changed from statistically significantly different to non-significantly (p&#x02009;=&#x02009;0.248) different. The affected Tables (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>, Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>, Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>), Figures (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">3</xref>, Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">4</xref>) and Supplementary material (Supplementary Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> and Supplementary Table&#x000a0;3) were remade and all updated with the correct numbers per quartile, correct odds ratios or hazard ratios and confidence intervals. The authors regret their mistake.</p><p id="Par4">Incorrect Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">3</xref> is given below.<fig id="Fig1"><label>Fig. 3</label><caption><p>Forest plot of annual hospital volume, hospital level and the chance of receiving metastatic surgery</p></caption><graphic xlink:href="12885_2025_14339_Fig1_HTML" id="MO1"/></fig></p><p id="Par5">Correct Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">3</xref> is given below.<fig id="Fig2"><label>Fig. 3</label><caption><p>Forest plot of annual hospital volume, hospital level and the chance of receiving metastatic surgery</p></caption><graphic xlink:href="12885_2025_14339_Fig2_HTML" id="MO2"/></fig></p><p id="Par6">Incorrect Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">4</xref> is given below.<fig id="Fig3"><label>Fig. 4</label><caption><p>Cumulative overall survival (OS) estimates by <bold>A</bold>) hospital volume, <bold>B</bold>) hospital level, <bold>C</bold>) metastatic surgery. <italic>Kaplan-Meier estimates of OS including 9,968 patients followed from diagnosis of synchronous metastatic colorectal cancer. The stratification by metastatic surgery was based on a delayed entry of patients in model to 270 days post diagnosis (n=5,993). P-value from log-rank test was p=0.001 for A and p&#x0003c;0.001 for B and C</italic></p></caption><graphic xlink:href="12885_2025_14339_Fig3_HTML" id="MO3"/></fig></p><p id="Par7">Correct Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref> is given below.<fig id="Fig4"><label>Fig. 4</label><caption><p>Cumulative overall survival (OS) estimates by <bold>A</bold>) hospital volume, <bold>B</bold>) hospital level, <bold>C</bold>) metastatic surgery. <italic>Kaplan-Meier estimates of OS including 9,968 patients followed from diagnosis of synchronous metastatic colorectal cancer. The stratification by metastatic surgery was based on a delayed entry of patients in model to 270 days post diagnosis (n=5,993). P-values from log-rank test were p&#x0003c;0.001 for A, B and C</italic></p></caption><graphic xlink:href="12885_2025_14339_Fig4_HTML" id="MO4"/></fig></p><p id="Par8">The incorrect Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> is given below.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Patient characteristics according to annual hospital volume of patients with metastatic colorectal cancer</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left"/><th align="left">First quartile<break/><italic>n</italic>&#x02009;=&#x02009;2,328</th><th align="left">Second quartile<break/><italic>n</italic>&#x02009;=&#x02009;2,591</th><th align="left">Third quartile<break/><italic>n</italic>&#x02009;=&#x02009;2,531</th><th align="left">Fourth quartile<break/><italic>n</italic>&#x02009;=&#x02009;2,518</th><th align="left">All<break/><italic>n</italic>&#x02009;=&#x02009;9,968</th><th align="left"><italic>P</italic>-value*</th></tr></thead><tbody><tr><td align="left" rowspan="2">Sex</td><td align="left">Male</td><td align="left">1,325 (57%)</td><td align="left">1,455 (56%)</td><td align="left">1,386 (55%)</td><td align="left">1,400 (56%)</td><td align="left">5,566 (56%)</td><td align="left">0.466</td></tr><tr><td align="left">Female</td><td align="left">1,003 (43%)</td><td align="left">1,136 (44%)</td><td align="left">1,145 (45%)</td><td align="left">1,118 (44%)</td><td align="left">4,402 (44%)</td><td align="left"/></tr><tr><td align="left" rowspan="4">Age</td><td align="left">Median (years)</td><td align="left">71</td><td align="left">70</td><td align="left">71</td><td align="left">69</td><td align="left">70</td><td align="left"/></tr><tr><td align="left">18&#x02013;64&#x000a0;years</td><td align="left">631 (27%)</td><td align="left">784 (30%)</td><td align="left">757 (30%)</td><td align="left">889 (35%)</td><td align="left">3,061 (31%)</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">65&#x02013;79&#x000a0;years</td><td align="left">1,182 (51%)</td><td align="left">1,265 (49%)</td><td align="left">1,221 (48%)</td><td align="left">1,169 (46%)</td><td align="left">4,837 (49%)</td><td align="left"/></tr><tr><td align="left">&#x02009;&#x02265;&#x02009;80&#x000a0;years</td><td align="left">515 (22%)</td><td align="left">542 (21%)</td><td align="left">553 (22%)</td><td align="left">460 (18%)</td><td align="left">2,070 (21%)</td><td align="left"/></tr><tr><td align="left" rowspan="3">Charlson comorbidity index</td><td align="left">0</td><td align="left">1,469 (63%)</td><td align="left">1,600 (62%)</td><td align="left">1,523 (60%)</td><td align="left">1,543 (61%)</td><td align="left">6,135 (62%)</td><td align="left">0.378</td></tr><tr><td align="left">1</td><td align="left">229 (10%)</td><td align="left">287 (11%)</td><td align="left">290 (11%)</td><td align="left">264 (10%)</td><td align="left">1,070 (11%)</td><td align="left"/></tr><tr><td align="left">&#x02009;&#x02265;&#x02009;2</td><td align="left">630 (27%)</td><td align="left">704 (27%)</td><td align="left">718 (28%)</td><td align="left">711 (28%)</td><td align="left">2,763 (28%)</td><td align="left"/></tr><tr><td align="left" rowspan="2">Year of diagnosis</td><td align="left">2009&#x02013;2012</td><td align="left">1,228 (55%)</td><td align="left">1,359 (52%)</td><td align="left">1,198 (47%)</td><td align="left">980 (39%)</td><td align="left">4,825 (48%)</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">2013&#x02013;2016</td><td align="left">1,040 (45%)</td><td align="left">1,232 (48%)</td><td align="left">1,333 (53%)</td><td align="left">1,538 (61%)</td><td align="left">5,143 (52%)</td><td align="left"/></tr><tr><td align="left" rowspan="3">Civil status **</td><td align="left">Married/registered partner</td><td align="left">1,258 (54%)</td><td align="left">1,416 (55%)</td><td align="left">1,329 (53%)</td><td align="left">1,309 (52%)</td><td align="left">4,654 (47%)</td><td align="left">0.348</td></tr><tr><td align="left">Not married: never married, divorced, widowed</td><td align="left">1,070 (46%)</td><td align="left">1,175 (45%)</td><td align="left">1,201 (47%)</td><td align="left">1,208 (48%)</td><td align="left">5,312 (53%)</td><td align="left"/></tr><tr><td align="left">Missing</td><td align="left">0 (0%)</td><td align="left">0 (0%)</td><td align="left">1 (0%)</td><td align="left">1 (0%)</td><td align="left">2 (0%)</td><td align="left"/></tr><tr><td align="left" rowspan="4">Highest level of commenced education **</td><td align="left">Primary school (maximum 9&#x000a0;years)</td><td align="left">909 (39%)</td><td align="left">1,011 (39%)</td><td align="left">965 (38%)</td><td align="left">775 (31%)</td><td align="left">3,660 (37%)</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left"><p>Secondary school</p><p>(3&#x02013;4 additional years)</p></td><td align="left">945 (41%)</td><td align="left">1,011 (39%)</td><td align="left">993 (39%)</td><td align="left">1,039 (41%)</td><td align="left">3,988 (40%)</td><td align="left"/></tr><tr><td align="left">Higher education</td><td align="left">459 (20%)</td><td align="left">531 (20%)</td><td align="left">550 (22%)</td><td align="left">680 (27%)</td><td align="left">2,220 (22%)</td><td align="left"/></tr><tr><td align="left">Missing</td><td align="left">14 (1%)</td><td align="left">38 (1%)</td><td align="left">24 (1%)</td><td align="left">24 (1%)</td><td align="left">100 (1%)</td><td align="left"/></tr><tr><td align="left" rowspan="5">Disposable income per family unit divided into annual quartiles. ***</td><td align="left">1st quartile</td><td align="left">676 (29%)</td><td align="left">653 (25%)</td><td align="left">624 (25%)</td><td align="left">543 (22%)</td><td align="left">2,496 (25%)</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">2nd quartile</td><td align="left">609 (26%)</td><td align="left">646 (25%)</td><td align="left">648 (26%)</td><td align="left">584 (23%)</td><td align="left">2,487 (25%)</td><td align="left"/></tr><tr><td align="left">3rd quartile</td><td align="left">569 (24%)</td><td align="left">685 (26%)</td><td align="left">633 (25%)</td><td align="left">605 (24%)</td><td align="left">2,492 (25%)</td><td align="left"/></tr><tr><td align="left">4th quartile</td><td align="left">474 (20%)</td><td align="left">607 (23%)</td><td align="left">625 (25%)</td><td align="left">785 (31%)</td><td align="left">2,491 (25%)</td><td align="left"/></tr><tr><td align="left">Missing</td><td align="left">0 (0%)</td><td align="left">0 (0%)</td><td align="left">1 (0%)</td><td align="left">1 (0%)</td><td align="left">2 (0%)</td><td align="left"/></tr></tbody></table><table-wrap-foot><p>Includes 9,968 patients diagnosed with metastatic colorectal cancer in 2009&#x02013;2016 in Sweden</p><p>*From chi square test</p><p>**Year of/up to 3&#x000a0;years before if missing</p><p>***Year before diagnosis or up to 3&#x000a0;years before or year of if missing</p></table-wrap-foot></table-wrap></p><p id="Par9">The correct Table&#x000a0;<xref rid="Tab2" ref-type="table">1</xref> is given below.<table-wrap id="Tab2"><label>Table&#x000a0;1</label><caption><p>Patient characteristics according to annual hospital volume of patients with metastatic colorectal cancer</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left"/><th align="left">First quartile<break/><italic>n</italic>&#x02009;=&#x02009;2,402</th><th align="left">Second quartile<break/><italic>n</italic>&#x02009;=&#x02009;2,439</th><th align="left">Third quartile<break/><italic>n</italic>&#x02009;=&#x02009;2,433</th><th align="left">Fourth quartile<break/><italic>n</italic>&#x02009;=&#x02009;2,694</th><th align="left">All<break/><italic>n</italic>&#x02009;=&#x02009;9,968</th><th align="left"><italic>P</italic>-value*</th></tr></thead><tbody><tr><td align="left" rowspan="2">Sex</td><td align="left">Male</td><td align="left">1,352 (56%)</td><td align="left">1,377 (56%)</td><td align="left">1,347 (55%)</td><td align="left">1,490 (55%)</td><td align="left">5,566 (56%)</td><td align="left">0.776</td></tr><tr><td align="left">Female</td><td align="left">1,050 (44%)</td><td align="left">1,062 (44%)</td><td align="left">1,086 (45%)</td><td align="left">1,204 (45%)</td><td align="left">4,402 (44%)</td><td align="left"/></tr><tr><td align="left" rowspan="4">Age</td><td align="left">Median (years)</td><td align="left">71</td><td align="left">70</td><td align="left">71</td><td align="left">69</td><td align="left">70</td><td align="left"/></tr><tr><td align="left">18&#x02013;64&#x000a0;years</td><td align="left">646 (27%)</td><td align="left">738 (30%)</td><td align="left">719 (30%)</td><td align="left">958 (36%)</td><td align="left">3,061 (31%)</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">65&#x02013;79&#x000a0;years</td><td align="left">1,221 (51%)</td><td align="left">1,180 (48%)</td><td align="left">1,178 (48%)</td><td align="left">1,258 (47%)</td><td align="left">4,837 (49%)</td><td align="left"/></tr><tr><td align="left">&#x02009;&#x02265;&#x02009;80&#x000a0;years</td><td align="left">535 (22%)</td><td align="left">521 (21%)</td><td align="left">536 (22%)</td><td align="left">478 (18%)</td><td align="left">2,070 (21%)</td><td align="left"/></tr><tr><td align="left" rowspan="3">Charlson comorbidity index</td><td align="left">0</td><td align="left">1,507 (63%)</td><td align="left">1,517(62%)</td><td align="left">1,454 (60%)</td><td align="left">1,657 (62%)</td><td align="left">6,135 (62%)</td><td align="left">0.157</td></tr><tr><td align="left">1</td><td align="left">238 (10%)</td><td align="left">266 (11%)</td><td align="left">292 (12%)</td><td align="left">274 (10%)</td><td align="left">1,070 (11%)</td><td align="left"/></tr><tr><td align="left">&#x02009;&#x02265;&#x02009;2</td><td align="left">657 (27%)</td><td align="left">656 (27%)</td><td align="left">687 (28%)</td><td align="left">763 (28%)</td><td align="left">2,763 (28%)</td><td align="left"/></tr><tr><td align="left" rowspan="2">Year of diagnosis</td><td align="left">2009&#x02013;2012</td><td align="left">1,157 (48%)</td><td align="left">1,173 (48%)</td><td align="left">1,219 (50%)</td><td align="left">1276(47%)</td><td align="left">4,825 (48%)</td><td align="left">0.248</td></tr><tr><td align="left">2013&#x02013;2016</td><td align="left">1,245 (52%)</td><td align="left">1,266 (52%)</td><td align="left">1,214 (50%)</td><td align="left">1,418 (53%)</td><td align="left">5,143 (52%)</td><td align="left"/></tr><tr><td align="left" rowspan="3">Civil status **</td><td align="left">Married/registered partner</td><td align="left">1,304 (54%)</td><td align="left">1,320 (54%)</td><td align="left">1,275 (52%)</td><td align="left">1,413 (52%)</td><td align="left">4,654 (47%)</td><td align="left">0.545</td></tr><tr><td align="left">Not married: never married, divorced, widowed</td><td align="left">1,098 (46%)</td><td align="left">1,119 (46%)</td><td align="left">1,157 (48%)</td><td align="left">1,280 (48%)</td><td align="left">5,312 (53%)</td><td align="left"/></tr><tr><td align="left">Missing</td><td align="left">0 (0%)</td><td align="left">0 (0%)</td><td align="left">1 (0%)</td><td align="left">1 (0%)</td><td align="left">2 (0%)</td><td align="left"/></tr><tr><td align="left" rowspan="4">Highest level of commenced education **</td><td align="left">Primary school (maximum 9&#x000a0;years)</td><td align="left">921 (38%)</td><td align="left">960 (39%)</td><td align="left">940 (39%)</td><td align="left">839 (31%)</td><td align="left">3,660 (37%)</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left"><p>Secondary school</p><p>(3&#x02013;4 additional years)</p></td><td align="left">979 (41%)</td><td align="left">958 (39%)</td><td align="left">959 (39%)</td><td align="left">1,092 (41%)</td><td align="left">3,988 (40%)</td><td align="left"/></tr><tr><td align="left">Higher education</td><td align="left">487 (20%)</td><td align="left">490 (20%)</td><td align="left">502 (21%)</td><td align="left">741 (28%)</td><td align="left">2,220 (22%)</td><td align="left"/></tr><tr><td align="left">Missing</td><td align="left">15 (1%)</td><td align="left">31 (1%)</td><td align="left">32 (1%)</td><td align="left">22 (1%)</td><td align="left">100 (1%)</td><td align="left"/></tr><tr><td align="left" rowspan="5">Disposable income per family unit divided into annual quartiles. ***</td><td align="left">1st quartile</td><td align="left">677 (28%)</td><td align="left">590 (24%)</td><td align="left">616 (25%)</td><td align="left">613 (22%)</td><td align="left">2,496 (25%)</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">2nd quartile</td><td align="left">635 (26%)</td><td align="left">629 (26%)</td><td align="left">602 (25%)</td><td align="left">621 (23%)</td><td align="left">2,487 (25%)</td><td align="left"/></tr><tr><td align="left">3rd quartile</td><td align="left">579 (24%)</td><td align="left">654 (27%)</td><td align="left">603 (25%)</td><td align="left">656 (24%)</td><td align="left">2,492 (25%)</td><td align="left"/></tr><tr><td align="left">4th quartile</td><td align="left">511 (21%)</td><td align="left">566 (23%)</td><td align="left">611 (25%)</td><td align="left">803 (30%)</td><td align="left">2,491 (25%)</td><td align="left"/></tr><tr><td align="left">Missing</td><td align="left">0 (0%)</td><td align="left">0 (0%)</td><td align="left">1 (0%)</td><td align="left">1 (0%)</td><td align="left">2 (0%)</td><td align="left"/></tr></tbody></table><table-wrap-foot><p>Includes 9,968 patients diagnosed with metastatic colorectal cancer in 2009&#x02013;2016 in Sweden</p><p>*From chi square test</p><p>**Year of/up to 3&#x000a0;years before if missing</p><p>***Year before diagnosis or up to 3&#x000a0;years before or year of if missing</p></table-wrap-foot></table-wrap></p><p id="Par10">The incorrect Table&#x000a0;<xref rid="Tab3" ref-type="table">2</xref> is given below.<table-wrap id="Tab3"><label>Table&#x000a0;2</label><caption><p>Hospital and tumour characteristics according to annual hospital volume of patients with metastatic colorectal cancer</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left"/><th align="left">First quartile<break/><italic>n</italic>&#x02009;=&#x02009;2,328</th><th align="left">Second quartile<break/><italic>n</italic>&#x02009;=&#x02009;2,591</th><th align="left">Third quartile<break/><italic>n</italic>&#x02009;=&#x02009;2,531</th><th align="left">Fourth quartile<break/><italic>n</italic>&#x02009;=&#x02009;2,518</th><th align="left">All <italic>n</italic>&#x02009;=&#x02009;9,968</th><th align="left"><italic>P</italic>-value*</th></tr></thead><tbody><tr><td align="left" rowspan="2">Hospital level</td><td align="left">University</td><td align="left">79 (3%)</td><td align="left">492 (19%)</td><td align="left">669 (26%)</td><td align="left">1,928 (77%)</td><td align="left">3,168 (32%)</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Non-university</td><td align="left">2,249 (97%)</td><td align="left">2,099 (81%)</td><td align="left">1,862 (74%)</td><td align="left">590 (23%)</td><td align="left">6,800 (68%)</td><td align="left"/></tr><tr><td align="left" rowspan="6">Hospital region</td><td align="left">1</td><td align="left">221 (9%)</td><td align="left">370 (14%)</td><td align="left">635 (25%)</td><td align="left">741 (29%)</td><td align="left">1,967 (20%)</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">2</td><td align="left">505 (22%)</td><td align="left">608 (23%)</td><td align="left">869 (34%)</td><td align="left">273 (11%)</td><td align="left">2,255 (23%)</td><td align="left"/></tr><tr><td align="left">3</td><td align="left">370 (16%)</td><td align="left">449 (17%)</td><td align="left">231 (9%)</td><td align="left">0 (0%)</td><td align="left">1,050 (11%)</td><td align="left"/></tr><tr><td align="left">4</td><td align="left">390 (17%)</td><td align="left">459 (18%)</td><td align="left">407 (16%)</td><td align="left">763 (30%)</td><td align="left">2,019 (20%)</td><td align="left"/></tr><tr><td align="left">5</td><td align="left">390 (17%)</td><td align="left">401 (15%)</td><td align="left">288 (11%)</td><td align="left">741 (29%)</td><td align="left">1,820 (18%)</td><td align="left"/></tr><tr><td align="left">6</td><td align="left">452 (19%)</td><td align="left">304 (12%)</td><td align="left">101 (4%)</td><td align="left">0 (0%)</td><td align="left">857 (9%)</td><td align="left"/></tr><tr><td align="left" rowspan="5">Primary tumour location</td><td align="left">Right colon</td><td align="left">615 (26%)</td><td align="left">637 (25%)</td><td align="left">643 (25%)</td><td align="left">676 (27%)</td><td align="left">2,568 (26%)</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Transverse colon</td><td align="left">314 (13%)</td><td align="left">292 (11%)</td><td align="left">316 (12%)</td><td align="left">306 (12%)</td><td align="left">1,227 (12%)</td><td align="left"/></tr><tr><td align="left">Left colon</td><td align="left">743 (32%)</td><td align="left">761 (29%)</td><td align="left">732 (29%)</td><td align="left">673 (27%)</td><td align="left">2,912 (29%)</td><td align="left"/></tr><tr><td align="left">Unknown location in colon</td><td align="left">21 (1%)</td><td align="left">19 (1%)</td><td align="left">9 (0%)</td><td align="left">19 (1%)</td><td align="left">68 (1%)</td><td align="left"/></tr><tr><td align="left">Rectum</td><td align="left">625 (27%)</td><td align="left">882 (34%)</td><td align="left">831 (33%)</td><td align="left">844 (34%)</td><td align="left">3,193 (32%)</td><td align="left"/></tr><tr><td align="left" rowspan="3">Pretherapeutic multidisciplinary team conference</td><td align="left">Yes</td><td align="left">1,507 (65%)</td><td align="left">1,967 (76%)</td><td align="left">1,950 (77%)</td><td align="left">2,011 (80%)</td><td align="left">7,435 (75%)</td><td align="left" rowspan="3">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">No</td><td align="left">812 (35%)</td><td align="left">621 (24%)</td><td align="left">570 (23%)</td><td align="left">498 (20%)</td><td align="left">2,510 (25%)</td></tr><tr><td align="left">Missing</td><td align="left">8 (0%)</td><td align="left">3 (0%)</td><td align="left">3 (0%)</td><td align="left">9 (0%)</td><td align="left">23 (0%)</td></tr><tr><td align="left" rowspan="2">Resection of primary tumour</td><td align="left">No</td><td align="left">1,128 (48%)</td><td align="left">1,349 (52%)</td><td align="left">1,397 (55%)</td><td align="left">1,322 (53%)</td><td align="left">5,196 (52%)</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Yes</td><td align="left">1,199 (52%)</td><td align="left">1,242 (48%)</td><td align="left">1,135 (45%)</td><td align="left">1,196 (47%)</td><td align="left">4,772 (48%)</td><td align="left"/></tr><tr><td align="left" rowspan="4">cT</td><td align="left">1&#x02013;3</td><td align="left">659 (28%)</td><td align="left">959 (37%)</td><td align="left">824 (33%)</td><td align="left">824 (34%)</td><td align="left">3,264 (33%)</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">4</td><td align="left">564 (24%)</td><td align="left">757 (29%)</td><td align="left">735 (29%)</td><td align="left">795 (32%)</td><td align="left">2,849 (29%)</td><td align="left"/></tr><tr><td align="left">X</td><td align="left">619 (27%)</td><td align="left">485 (19%)</td><td align="left">500 (20%)</td><td align="left">611 (24%)</td><td align="left">2,218 (22%)</td><td align="left"/></tr><tr><td align="left">Missing</td><td align="left">486 (21%)</td><td align="left">290 (15%)</td><td align="left">472 (19%)</td><td align="left">288 (11%)</td><td align="left">1,637 (16%)</td><td align="left"/></tr><tr><td align="left" rowspan="4">cN</td><td align="left">0</td><td align="left">450 (19%)</td><td align="left">531 (20%)</td><td align="left">413 (16%)</td><td align="left">401 (16%)</td><td align="left">1,795 (18%)</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">1&#x02013;2</td><td align="left">1,099 (47%)</td><td align="left">1,434 (55%)</td><td align="left">1,521 (60%)</td><td align="left">1,362 (54%)</td><td align="left">5,414 (54%)</td><td align="left"/></tr><tr><td align="left">X</td><td align="left">660 (28%)</td><td align="left">543 (21%)</td><td align="left">540 (21%)</td><td align="left">702 (28%)</td><td align="left">2,447 (25%)</td><td align="left"/></tr><tr><td align="left">Missing</td><td align="left">119 (5%)</td><td align="left">83 (3%)</td><td align="left">57 (2%)</td><td align="left">53 (2%)</td><td align="left">312 (3%)</td><td align="left"/></tr><tr><td align="left" rowspan="5">Metastatic location</td><td align="left">Liver</td><td align="left">744 (32%)</td><td align="left">913 (35%)</td><td align="left">908 (36%)</td><td align="left">805 (32%)</td><td align="left">3,370 (34%)</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Lung</td><td align="left">205 (9%)</td><td align="left">176 (7%)</td><td align="left">170 (7%)</td><td align="left">128 (5%)</td><td align="left">679 (7%)</td><td align="left"/></tr><tr><td align="left">Peritoneum</td><td align="left">62 (3%)</td><td align="left">70 (3%)</td><td align="left">85 (3%)</td><td align="left">111 (4%)</td><td align="left">328 (3%)</td><td align="left"/></tr><tr><td align="left">Other</td><td align="left">73 (3%)</td><td align="left">93 (4%)</td><td align="left">83 (3%)</td><td align="left">105 (4%)</td><td align="left">354 (4%)</td><td align="left"/></tr><tr><td align="left">Multiple locations</td><td align="left">1,244 (53%)</td><td align="left">1,339 (52%)</td><td align="left">1,285 (51%)</td><td align="left">1,369 (54%)</td><td align="left">5,237 (53%)</td><td align="left"/></tr></tbody></table><table-wrap-foot><p>Includes 9,968 patients diagnosed with metastatic colorectal cancer in 2009&#x02013;2016 in Sweden</p><p>*From chi square test</p><p><italic>Abbreviations:</italic>
<italic>cN</italic> clinical nodal status, <italic>CT</italic> clinical tumour status</p></table-wrap-foot></table-wrap></p><p id="Par11">The correct Table&#x000a0;<xref rid="Tab4" ref-type="table">2</xref> is given below
<table-wrap id="Tab4"><label>Table 2</label><caption><p>Hospital and tumour characteristics according to annual hospital volume of patients with metastatic colorectal cancer</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left"/><th align="left">First quartile<break/><italic>n</italic>&#x02009;=&#x02009;2,402</th><th align="left">Second quartile<break/><italic>n</italic>&#x02009;=&#x02009;2,439</th><th align="left">Third quartile<break/><italic>n</italic>&#x02009;=&#x02009;2,433</th><th align="left">Fourth quartile<break/><italic>n</italic>&#x02009;=&#x02009;2,694</th><th align="left">All <italic>n</italic>&#x02009;=&#x02009;9,968</th><th align="left"><italic>P</italic>-value*</th></tr></thead><tbody><tr><td align="left" rowspan="2">Hospital level</td><td align="left">University</td><td align="left">105 (4%)</td><td align="left">356 (15%)</td><td align="left">537 22%)</td><td align="left">2,170 81%)</td><td align="left">3,168 (32%)</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Non-university</td><td align="left">2,297 (96%)</td><td align="left">2,083 (85%)</td><td align="left">1,896 (78%)</td><td align="left">524 (19%)</td><td align="left">6,800 (68%)</td><td align="left"/></tr><tr><td align="left" rowspan="6">Hospital region</td><td align="left">1</td><td align="left">221 (9%)</td><td align="left">281 (12%)</td><td align="left">592 (24%)</td><td align="left">873 (32%)</td><td align="left">1,967 (20%)</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">2</td><td align="left">453 (19%)</td><td align="left">706 (29%)</td><td align="left">762 (31%)</td><td align="left">334 (12%)</td><td align="left">2,255 (23%)</td><td align="left"/></tr><tr><td align="left">3</td><td align="left">373 (16%)</td><td align="left">489 (20%)</td><td align="left">101 (4%)</td><td align="left">87(3%)</td><td align="left">1,050 (11%)</td><td align="left"/></tr><tr><td align="left">4</td><td align="left">395 (16%)</td><td align="left">368 (15%)</td><td align="left">543 (22%)</td><td align="left">713 (26%)</td><td align="left">2,019 (20%)</td><td align="left"/></tr><tr><td align="left">5</td><td align="left">439 (18%)</td><td align="left">357 (15%)</td><td align="left">337 (14%)</td><td align="left">687 (26%)</td><td align="left">1,820 (18%)</td><td align="left"/></tr><tr><td align="left">6</td><td align="left">439 (18%)</td><td align="left">238 (10%)</td><td align="left">98 (4%)</td><td align="left">0 (0%)</td><td align="left">857 (9%)</td><td align="left"/></tr><tr><td align="left" rowspan="5">Primary tumour location</td><td align="left">Right colon</td><td align="left">647 (27%)</td><td align="left">577 (24%)</td><td align="left">630 (26%)</td><td align="left">717 (27%)</td><td align="left">2,568 (26%)</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Transverse colon</td><td align="left">314 (13%)</td><td align="left">274 (11%)</td><td align="left">317 (13%)</td><td align="left">323 (12%)</td><td align="left">1,227 (12%)</td><td align="left"/></tr><tr><td align="left">Left colon</td><td align="left">770 (32%)</td><td align="left">711 (29%)</td><td align="left">705 (29%)</td><td align="left">723 (27%)</td><td align="left">2,912 (29%)</td><td align="left"/></tr><tr><td align="left">Unknown location in colon</td><td align="left">21 (1%)</td><td align="left">19 (1%)</td><td align="left">9 (0%)</td><td align="left">19 (1%)</td><td align="left">68 (1%)</td><td align="left"/></tr><tr><td align="left">Rectum</td><td align="left">650 (27%)</td><td align="left">858 (35%)</td><td align="left">772 (32%)</td><td align="left">912 (34%)</td><td align="left">3,193 (32%)</td><td align="left"/></tr><tr><td align="left" rowspan="3">Pretherapeutic multidisciplinary team conference</td><td align="left">Yes</td><td align="left">1,607 (67%)</td><td align="left">1,852 (76%)</td><td align="left">1,859 (76%)</td><td align="left">2,117 (79%)</td><td align="left">7,435 (75%)</td><td align="left" rowspan="3">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">No</td><td align="left">787 (33%)</td><td align="left">584 (24%)</td><td align="left">572 (24%)</td><td align="left">567 (21%)</td><td align="left">2,510 (25%)</td></tr><tr><td align="left">Missing</td><td align="left">8 (0%)</td><td align="left">3 (0%)</td><td align="left">2 (0%)</td><td align="left">10(0%)</td><td align="left">23 (0%)</td></tr><tr><td align="left" rowspan="2">Resection of primary tumour</td><td align="left">No</td><td align="left">1,174 (48%)</td><td align="left">1,297 (53%)</td><td align="left">1,360 (56%)</td><td align="left">1,365 (51%)</td><td align="left">5,196 (52%)</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Yes</td><td align="left">1,228 (51%)</td><td align="left">1,142 (47%)</td><td align="left">1,073 (44%)</td><td align="left">1,329 (49%)</td><td align="left">4,772 (48%)</td><td align="left"/></tr><tr><td align="left" rowspan="4">cT</td><td align="left">1&#x02013;3</td><td align="left">696 (29%)</td><td align="left">912 (37%)</td><td align="left">812 (33%)</td><td align="left">846 (34%)</td><td align="left">3,266 (33%)</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">4</td><td align="left">598 (25%)</td><td align="left">713 (29%)</td><td align="left">721 (30%)</td><td align="left">819 (31%)</td><td align="left">2,851 (29%)</td><td align="left"/></tr><tr><td align="left">X</td><td align="left">637 (27%)</td><td align="left">445 (18%)</td><td align="left">481 (20%)</td><td align="left">652 (24%)</td><td align="left">2,218 (22%)</td><td align="left"/></tr><tr><td align="left">Missing</td><td align="left">471 (20%)</td><td align="left">369 (15%)</td><td align="left">419 (17%)</td><td align="left">377 (14%)</td><td align="left">1,637 (16%)</td><td align="left"/></tr><tr><td align="left" rowspan="4">cN</td><td align="left">0</td><td align="left">475 (20%)</td><td align="left">469 (19%)</td><td align="left">447 (18%)</td><td align="left">404 (15%)</td><td align="left">1,795 (18%)</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">1&#x02013;2</td><td align="left">1,170 (49%)</td><td align="left">1,372 (56%)</td><td align="left">1,433 (59%)</td><td align="left">1,441 (53%)</td><td align="left">5,414 (54%)</td><td align="left"/></tr><tr><td align="left">X</td><td align="left">641 (27%)</td><td align="left">520 (21%)</td><td align="left">502 (21%)</td><td align="left">782 (29%)</td><td align="left">2,447 (25%)</td><td align="left"/></tr><tr><td align="left">Missing</td><td align="left">116 (5%)</td><td align="left">78 (3%)</td><td align="left">51 (2%)</td><td align="left">67 (2%)</td><td align="left">312 (3%)</td><td align="left"/></tr><tr><td align="left" rowspan="5">Metastatic location</td><td align="left">Liver</td><td align="left">772 (32%)</td><td align="left">826 (34%)</td><td align="left">879 (36%)</td><td align="left">893 (33%)</td><td align="left">3,370 (34%)</td><td align="left">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Lung</td><td align="left">210 (9%)</td><td align="left">177 (7%)</td><td align="left">159 (7%)</td><td align="left">133 (5%)</td><td align="left">679 (7%)</td><td align="left"/></tr><tr><td align="left">Peritoneum</td><td align="left">68 (3%)</td><td align="left">55 (2%)</td><td align="left">86 (4%)</td><td align="left">119 (4%)</td><td align="left">328 (3%)</td><td align="left"/></tr><tr><td align="left">Other</td><td align="left">77 (3%)</td><td align="left">91 (4%)</td><td align="left">72 (3%)</td><td align="left">114 (4%)</td><td align="left">354 (4%)</td><td align="left"/></tr><tr><td align="left">Multiple locations</td><td align="left">1,275 (53%)</td><td align="left">1,290 (53%)</td><td align="left">1,237 (51%)</td><td align="left">1,435 (53%)</td><td align="left">5,237 (53%)</td><td align="left"/></tr></tbody></table><table-wrap-foot><p>Includes 9,968 patients diagnosed with metastatic colorectal cancer in 2009&#x02013;2016 in Sweden</p><p>*From chi square test</p><p><italic>Abbreviations</italic>: <italic>cN</italic> clinical nodal status, <italic>CT</italic> clinical tumour status</p></table-wrap-foot></table-wrap></p><p id="Par12">The incorrect Table&#x000a0;<xref rid="Tab5" ref-type="table">3</xref> is given below
<table-wrap id="Tab5"><label>Table 3</label><caption><p>Cox regression model estimates of all-cause mortality hazard ratios (HRs) with 95% confidence intervals (CIs)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left"/><th align="left"><bold>Univariable</bold></th><th align="left"><bold>First model</bold>.<sup><bold>1</bold></sup></th><th align="left"><bold>Second model</bold>.<sup><bold>2</bold></sup></th></tr><tr><th align="left"/><th align="left"/><th align="left">HR* (95% CI)</th><th align="left">HR* (95% CI)</th><th align="left">HR* (95% CI)</th></tr></thead><tbody><tr><td align="left">Hospital mCRC case load</td><td align="left">1<sup>st</sup> quartile</td><td align="left">1</td><td align="left">1</td><td align="left">1</td></tr><tr><td align="left"/><td align="left">2<sup>nd</sup> quartile</td><td align="left"><bold>0.93 (0.87&#x02013;0.99)</bold></td><td align="left">1.01 (0.95&#x02013;1.07)</td><td align="left">1.04 (0.98&#x02013;1.11)</td></tr><tr><td align="left"/><td align="left">3<sup>rd</sup> quartile</td><td align="left">0.97 (0.92&#x02013;1.04)</td><td align="left">1.02 (0.96&#x02013;1.09)</td><td align="left"><bold>1.07 (1.00&#x02013;1.14)</bold></td></tr><tr><td align="left"/><td align="left">4<sup>th</sup> quartile</td><td align="left"><bold>0.87 (0.82&#x02013;0.93)</bold></td><td align="left"><bold>0.92 (0.86&#x02013;0.98)</bold></td><td align="left">1.06 (0.98&#x02013;1.14)</td></tr><tr><td align="left">Hospital level</td><td align="left">Non-university</td><td align="left">1</td><td align="left">1</td><td align="left">1</td></tr><tr><td align="left"/><td align="left">University</td><td align="left"><bold>0.81 (0.78&#x02013;0.85)</bold></td><td align="left"><bold>0.85 (0.81&#x02013;0.89)</bold></td><td align="left"><bold>0.83 (0.78&#x02013;0.88)</bold></td></tr></tbody></table><table-wrap-foot><p>Model includes 9,968 patients with synchronous colorectal cancer metastases</p><p>*Adjusted for time since diagnosis</p><p><sup>1</sup>One exposure (hospital volume/ hospital level) and adjusted for sex (male, female), age (categorized: 18&#x02013;64,65&#x02013;79,&#x02009;&#x02265;&#x02009;80&#x000a0;years), Charlson comorbidity index (0,1,&#x02009;&#x02265;&#x02009;2), Primary tumour location (right colon, transverse colon, left colon, colon unknown location in colon, rectum), cT (1&#x02013;3, 4, X) cN, (0, 1&#x02013;2, X), metastases (single, multiple), civil status (married, not married), education (primary, secondary, higher education), annual income (quartiles), year of diagnosis. Missing data handled using missing indicator method</p><p><sup>2</sup>Model of both exposures, adjusted as above</p></table-wrap-foot></table-wrap></p><p id="Par13">The correct Table&#x000a0;<xref rid="Tab6" ref-type="table">3</xref> is given below.<table-wrap id="Tab6"><label>Table&#x000a0;3</label><caption><p>Cox regression model estimates of all-cause mortality hazard ratios (HRs) with 95% confidence intervals (CIs)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left"/><th align="left"><bold>Univariable</bold></th><th align="left"><bold>First model </bold><sup><bold>1</bold></sup></th><th align="left"><bold>Second model</bold><sup><bold>2</bold></sup></th></tr><tr><th align="left"/><th align="left"/><th align="left">HR* (95% CI)</th><th align="left">HR* (95% CI)</th><th align="left">HR* (95% CI)</th></tr></thead><tbody><tr><td align="left">Hospital mCRC case load</td><td align="left">1<sup>st</sup> quartile</td><td align="left">1</td><td align="left">1</td><td align="left">1</td></tr><tr><td align="left"/><td align="left">2<sup>nd</sup> quartile</td><td align="left"><bold>0.94 (0.88&#x02013;1.00)</bold></td><td align="left">1.00 (0.94&#x02013;1.07)</td><td align="left">1.02 (0.96&#x02013;1.09)</td></tr><tr><td align="left"/><td align="left">3<sup>rd</sup> quartile</td><td align="left">1.00 (0.95&#x02013;1.07)</td><td align="left">1.06 (0.99&#x02013;1.12)</td><td align="left"><bold>1.09 (1.02&#x02013;1.16)</bold></td></tr><tr><td align="left"/><td align="left">4<sup>th</sup> quartile</td><td align="left"><bold>0.87 (0.82&#x02013;0.93)</bold></td><td align="left"><bold>0.90 (0.85&#x02013;0.96)</bold></td><td align="left">1.04 (0.96&#x02013;1.12)</td></tr><tr><td align="left">Hospital level</td><td align="left">Non-university</td><td align="left">1</td><td align="left">1</td><td align="left">1</td></tr><tr><td align="left"/><td align="left">University</td><td align="left"><bold>0.81 (0.78&#x02013;0.85)</bold></td><td align="left"><bold>0.85 (0.81&#x02013;0.89)</bold></td><td align="left"><bold>0.84 (0.79&#x02013;0.89)</bold></td></tr></tbody></table><table-wrap-foot><p>Model includes 9,968 patients with synchronous colorectal cancer metastases</p><p>*Adjusted for time since diagnosis</p><p><sup>1</sup>One exposure (hospital volume/ hospital level) and adjusted for sex (male, female), age (categorized: 18&#x02013;64,65&#x02013;79,&#x02009;&#x02265;&#x02009;80&#x000a0;years), Charlson comorbidity index (0,1,&#x02009;&#x02265;&#x02009;2), Primary tumour location (right colon, transverse colon, left colon, colon unknown location in colon, rectum), cT (1&#x02013;3, 4, X) cN, (0, 1&#x02013;2, X), metastases (single, multiple), civil status (married, not married), education (primary, secondary, higher education), annual income (quartiles), year of diagnosis. Missing data handled using missing indicator method</p><p><sup>2</sup>Model of both exposures, adjusted as above</p></table-wrap-foot></table-wrap></p><p id="Par14">The incorrect Supplementary Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> is given below.</p><p id="Par15">Supplementary Table&#x000a0;2. Additional treatment-associated patient characteristics for 9,968 patients with synchronous metastatic colorectal cancer (mCRC) according to the managing hospitals&#x02019; annual incident number of patients with mCRC divided into 4 quartiles.
<table-wrap id="Taba"><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left"/><th align="left">1st quartile<break/>n&#x02009;=&#x02009;2,328</th><th align="left">2nd quartile<break/>n&#x02009;=&#x02009;2,591</th><th align="left">3rd quartile<break/>n&#x02009;=&#x02009;2,531</th><th align="left">4th quartile<break/>n&#x02009;=&#x02009;2,518</th><th align="left">All n&#x02009;=&#x02009;9,968</th><th align="left">P-value</th></tr></thead><tbody><tr><td align="left" rowspan="5">ASA class</td><td align="left">1</td><td align="left">159 (7%)</td><td align="left">148 (6%)</td><td align="left">165 (7%)</td><td align="left">117 (5%)</td><td align="left">589 (6%)</td><td align="left" rowspan="5">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">2</td><td align="left">622 (27%)</td><td align="left">668 (26%)</td><td align="left">607 (24%)</td><td align="left">619 (25%)</td><td align="left">2,516 (25%)</td></tr><tr><td align="left">3</td><td align="left">386 (17%)</td><td align="left">386 (15%)</td><td align="left">395 (16%)</td><td align="left">493 (20%)</td><td align="left">1,660 (17%)</td></tr><tr><td align="left">4&#x02013;5</td><td align="left">59 (3%)</td><td align="left">30 (1%)</td><td align="left">51 (2%)</td><td align="left">61 (2%)</td><td align="left">201 (2%)</td></tr><tr><td align="left">Missing</td><td align="left">1,102 (47%)</td><td align="left">1,359 (52%)</td><td align="left">1,313 (52%)</td><td align="left">1,228 (49%)</td><td align="left">5,002 (50%)</td></tr><tr><td align="left" rowspan="3">Neoadjuvant treatment for metastatic colon cancer*</td><td align="left">No</td><td align="left">1,476 (87%)</td><td align="left">1 431 (84%)</td><td align="left">1 457 (86%)</td><td align="left">1 303 (78%)</td><td align="left">5,667 (84%)</td><td align="left" rowspan="3">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Yes</td><td align="left">200 (12%)</td><td align="left">266 (16%)</td><td align="left">233 (14%)</td><td align="left">254 (15%)</td><td align="left">952 (14%)</td></tr><tr><td align="left">Missing</td><td align="left">17 (1%)</td><td align="left">12 (1%)</td><td align="left">10 (1%)</td><td align="left">117 (7%)</td><td align="left">156 (2%)</td></tr><tr><td align="left" rowspan="5">Neoadjuvant treatment for metastatic rectal cancer*</td><td align="left">No</td><td align="left">387 (61%)</td><td align="left">458 (52%)</td><td align="left">453 (55%)</td><td align="left">411 (49%)</td><td align="left">411 (49%)</td><td align="left" rowspan="5">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Chemotherapy</td><td align="left">77 (12%)</td><td align="left">76 (9%)</td><td align="left">69 (8%)</td><td align="left">45 (5%)</td><td align="left">267 (8%)</td></tr><tr><td align="left">Radiotherapy</td><td align="left">63 (10%)</td><td align="left">119 (14%)</td><td align="left">107 (13%)</td><td align="left">96 (11%)</td><td align="left">385<underline> (12%)</underline></td></tr><tr><td align="left">Combination</td><td align="left">95 (15%)</td><td align="left">220 (25%)</td><td align="left">194 (23%)</td><td align="left">240 (28%)</td><td align="left">750 (23%)</td></tr><tr><td align="left">Missing</td><td align="left">13 (2%)</td><td align="left">9 (1%)</td><td align="left">8 (1%)</td><td align="left">52 (6%)</td><td align="left">82 (3%)</td></tr><tr><td align="left">pT (if resected)</td><td align="left">1&#x02013;3</td><td align="left">630 (53%)</td><td align="left">672 (54%)</td><td align="left">606 (53%)</td><td align="left">502 (42%)</td><td align="left">2,410 (51%)</td><td align="left" rowspan="3">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left"/><td align="left">4</td><td align="left">452 (38%)</td><td align="left">425 (34%)</td><td align="left">397 (35%)</td><td align="left">539 (45%)</td><td align="left">1,813 (38%)</td></tr><tr><td align="left"/><td align="left">X/Missing</td><td align="left">117 (10%)</td><td align="left">145 (12%)</td><td align="left">132 (12%)</td><td align="left">155 (13%)</td><td align="left">549 (12%)</td></tr><tr><td align="left">pN (if resected)</td><td align="left">0</td><td align="left">234 (20%)</td><td align="left">249 (20%)</td><td align="left">268 (24%)</td><td align="left">242 (20%)</td><td align="left">993 (21%)</td><td align="left" rowspan="4">0.003</td></tr><tr><td align="left"/><td align="left">1</td><td align="left">334 (28%)</td><td align="left">382 (31%)</td><td align="left">332 (29%)</td><td align="left">383 (32%)</td><td align="left">1,431 (30%)</td></tr><tr><td align="left"/><td align="left">2</td><td align="left">507 (42%)</td><td align="left">462 (37%)</td><td align="left">404 (36%)</td><td align="left">414 (35%)</td><td align="left">1,787 (37%)</td></tr><tr><td align="left"/><td align="left">X/missing</td><td align="left">124 (10%)</td><td align="left">149 (12%)</td><td align="left">131 (12%)</td><td align="left">157 (13%)</td><td align="left">561 (12%)</td></tr><tr><td align="left" rowspan="5">Surgery of metastases (with or without primary tumour resection)</td><td align="left">Liver**</td><td align="left">263 (11%)</td><td align="left">412 (16%)</td><td align="left">375 (15%)</td><td align="left">366 (15%)</td><td align="left">1,416 (14%)</td><td align="left" rowspan="5">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Lung**</td><td align="left">23 (1%)</td><td align="left">29 (1%)</td><td align="left">34 (1%)</td><td align="left">42 (2%)</td><td align="left">128 (1%)</td></tr><tr><td align="left">Peritoneal</td><td align="left">30 (1%)</td><td align="left">17 (1%)</td><td align="left">28 (1%)</td><td align="left">125 (5%)</td><td align="left">200 (2%)</td></tr><tr><td align="left">Combination**</td><td align="left">9 (0%)</td><td align="left">10 (0%)</td><td align="left">9 (0%)</td><td align="left">25 (1%)</td><td align="left">53 (1%)</td></tr><tr><td align="left">No</td><td align="left">2,002 (86%)</td><td align="left">2,123 (82%)</td><td align="left">2,086 (82%)</td><td align="left">1,960 (78%)</td><td align="left">8,171 (82%)</td></tr></tbody></table><table-wrap-foot><p>*Data unspecified on whether the neoadjuvant treatment was given for the primary tumour or the metastases or both</p><p>**A total of 46 patients who underwent surgery for liver metastases (of which one had combination metastatic surgery) received solely non-surgical locally ablative therapy (percutaneous destruction or embolisation treatment) and four patients with lung metastases had solely non-surgical treatment (stereotactic body radiation, SBRT). The solely non-surgical locally ablative treatments constituted 3% (n&#x02009;=&#x02009;50/1797) of the patients treated with metastatic surgery</p><p>Abbreviations: ASA (American Society of Anaesthesiologists), pN (pathological nodal status), pT (pathological tumour status).</p></table-wrap-foot></table-wrap></p><p id="Par16">The correct Supplementary Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> is given below.</p><p id="Par17">Supplementary Table&#x000a0;2. Additional treatment-associated patient characteristics for 9,968 patients with synchronous metastatic colorectal cancer (mCRC) according to the managing hospitals&#x02019; annual incident number of patients with mCRC divided into 4 quartiles.
<table-wrap id="Tabb"><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left"/><th align="left">1st quartile<break/>n&#x02009;=&#x02009;2,402</th><th align="left">2nd quartile<break/>n&#x02009;=&#x02009;2,439</th><th align="left">3rd quartile<break/>n&#x02009;=&#x02009;2,433</th><th align="left">4th quartile<break/>n&#x02009;=&#x02009;2,694</th><th align="left">All n&#x02009;=&#x02009;9,968</th><th align="left">P-value</th></tr></thead><tbody><tr><td align="left" rowspan="5">ASA class</td><td align="left">1</td><td align="left">153 (6%)</td><td align="left">135 (6%)</td><td align="left">156 (6%)</td><td align="left">145 (5%)</td><td align="left">589 (6%)</td><td align="left" rowspan="5">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">2</td><td align="left">627 (26%)</td><td align="left">624 (26%)</td><td align="left">584 (24%)</td><td align="left">681 (25%)</td><td align="left">2,516 (25%)</td></tr><tr><td align="left">3</td><td align="left">398 (17%)</td><td align="left">349 (14%)</td><td align="left">375 (15%)</td><td align="left">538 (20%)</td><td align="left">1,660 (17%)</td></tr><tr><td align="left">4&#x02013;5</td><td align="left">54 (2%)</td><td align="left">33 (1%)</td><td align="left">45 (2%)</td><td align="left">69 (3%)</td><td align="left">201 (2%)</td></tr><tr><td align="left">Missing</td><td align="left">1,179 (49%)</td><td align="left">1,359 (52%)</td><td align="left">1,273 (52%)</td><td align="left">1,228 (49%)</td><td align="left">5,002 (50%)</td></tr><tr><td align="left" rowspan="3">Neoadjuvant treatment for metastatic colon cancer*</td><td align="left">No</td><td align="left">1,476 (87%)</td><td align="left">1 431 (84%)</td><td align="left">1 457 (86%)</td><td align="left">1 303 (78%)</td><td align="left">5,667 (84%)</td><td align="left" rowspan="3">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Yes</td><td align="left">200 (12%)</td><td align="left">266 (16%)</td><td align="left">233 (14%)</td><td align="left">254 (15%)</td><td align="left">952 (14%)</td></tr><tr><td align="left">Missing</td><td align="left">17 (1%)</td><td align="left">12 (1%)</td><td align="left">10 (1%)</td><td align="left">117 (7%)</td><td align="left">156 (2%)</td></tr><tr><td align="left" rowspan="5">Neoadjuvant treatment for metastatic rectal cancer*</td><td align="left">No</td><td align="left">400 (62%)</td><td align="left">445 (52%)</td><td align="left">448 (58%)</td><td align="left">416 (46%)</td><td align="left">1709 (54%)</td><td align="left" rowspan="5">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Chemotherapy</td><td align="left">76 (12%)</td><td align="left">67 (8%)</td><td align="left">62 (8%)</td><td align="left">62 (7%)</td><td align="left">267 (8%)</td></tr><tr><td align="left">Radiotherapy</td><td align="left">61 (9%)</td><td align="left">115 (13%)</td><td align="left">93 (12%)</td><td align="left">116 (13%)</td><td align="left">385<underline> (12%)</underline></td></tr><tr><td align="left">Combination</td><td align="left">103 (16%)</td><td align="left">220 (26%)</td><td align="left">160 (21%)</td><td align="left">266 (29%)</td><td align="left">749 (23%)</td></tr><tr><td align="left">Missing</td><td align="left">10 (2%)</td><td align="left">11 (1%)</td><td align="left">9 (1%)</td><td align="left">52 (6%)</td><td align="left">82 (3%)</td></tr><tr><td align="left">pT (if resected)</td><td align="left">1&#x02013;3</td><td align="left">641 (52%)</td><td align="left">638 (56%)</td><td align="left">544 (51%)</td><td align="left">588 (44%)</td><td align="left">2,411 (51%)</td><td align="left" rowspan="3">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left"/><td align="left">4</td><td align="left">458 (37%)</td><td align="left">365 (32%)</td><td align="left">413 (38%)</td><td align="left">576 (43%)</td><td align="left">1,812 (38%)</td></tr><tr><td align="left"/><td align="left">X/Missing</td><td align="left">129 (11%)</td><td align="left">139 (12%)</td><td align="left">116 (11%)</td><td align="left">165 (12%)</td><td align="left">549 (12%)</td></tr><tr><td align="left">pN (if resected)</td><td align="left">0</td><td align="left">234 (19%)</td><td align="left">240 (21%)</td><td align="left">240 (22%)</td><td align="left">282 (21%)</td><td align="left">996 (21%)</td><td align="left" rowspan="4">0.141</td></tr><tr><td align="left"/><td align="left">1</td><td align="left">358 (29%)</td><td align="left">341 (30%)</td><td align="left">309 (29%)</td><td align="left">421 (32%)</td><td align="left">1,429 (30%)</td></tr><tr><td align="left"/><td align="left">2</td><td align="left">501 (41%)</td><td align="left">420 (37%)</td><td align="left">404 (38%)</td><td align="left">461 (35%)</td><td align="left">1,786 (37%)</td></tr><tr><td align="left"/><td align="left">X/missing</td><td align="left">135 (11%)</td><td align="left">141 (12%)</td><td align="left">120 (11%)</td><td align="left">165 (12%)</td><td align="left">561 (12%)</td></tr><tr><td align="left" rowspan="5">Surgery of metastases (with or without primary tumour resection)</td><td align="left">Liver**</td><td align="left">273 (11%)</td><td align="left">377 (15%)</td><td align="left">348 (14%)</td><td align="left">418 (16%)</td><td align="left">1,416 (14%)</td><td align="left" rowspan="5">&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left">Lung**</td><td align="left">24 (1%)</td><td align="left">28 (1%)</td><td align="left">39 (2%)</td><td align="left">37 (1%)</td><td align="left">128 (1%)</td></tr><tr><td align="left">Peritoneal</td><td align="left">31 (1%)</td><td align="left">17 (1%)</td><td align="left">25 (1%)</td><td align="left">127 (5%)</td><td align="left">200 (2%)</td></tr><tr><td align="left">Combination**</td><td align="left">10 (0%)</td><td align="left">7 (0%)</td><td align="left">10 (0%)</td><td align="left">26 (1%)</td><td align="left">53 (1%)</td></tr><tr><td align="left">No</td><td align="left">2,064 (86%)</td><td align="left">2,010 (82%)</td><td align="left">2,011 (83%)</td><td align="left">2,086 (77%)</td><td align="left">8,171 (82%)</td></tr></tbody></table><table-wrap-foot><p>*Data unspecified on whether the neoadjuvant treatment was given for the primary tumour or the metastases or both</p><p>**A total of 46 patients who underwent surgery for liver metastases (of which one had combination metastatic surgery) received solely non-surgical locally ablative therapy (percutaneous destruction or embolisation treatment) and four patients with lung metastases had solely non-surgical treatment (stereotactic body radiation, SBRT). The solely non-surgical locally ablative treatments constituted 3% (n&#x02009;=&#x02009;50/1797) of the patients treated with metastatic surgery</p><p>Abbreviations: ASA (American Society of Anaesthesiologists), pN (pathological nodal status), pT (pathological tumour status)</p></table-wrap-foot></table-wrap></p><p id="Par18">The incorrect Supplementary Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> is given below.</p><p id="Par19">Supplementary Table&#x000a0;3. Summary table of results.
<table-wrap id="Tabc"><table frame="hsides" rules="groups"><thead><tr><th align="left">Analysis</th><th align="left">Outcome</th><th align="left" colspan="2">Exposure</th><th align="left">Results</th></tr></thead><tbody><tr><td align="left" rowspan="3">Multivariable logistic regression adjusted</td><td align="left" rowspan="3">Metastatic surgery</td><td align="left" rowspan="3">Hospital volume in quartiles (qts)</td><td align="left">2nd qt vs 1st qt</td><td align="left">OR (95% CI): <bold>1.28 (1.08&#x02013;1.52)</bold></td></tr><tr><td align="left">3rd qt vs 1st qt</td><td align="left">OR (95% CI):<bold> 1.33 (1.12&#x02013;1.58)</bold></td></tr><tr><td align="left">4th qt vs 1st qt</td><td align="left">OR (95% CI):<bold> 1.68 (1.42&#x02013;1.98)</bold></td></tr><tr><td align="left">Multivariable logistic regression adjusted</td><td align="left">Metastatic surgery</td><td align="left">Hospital level</td><td align="left">University vs non-university</td><td align="left">OR (95% CI): <bold>1.89 (1.68&#x02013;2.12)</bold></td></tr><tr><td align="left" rowspan="4">Multivariable logistic regression adjusted for both exposures</td><td align="left" rowspan="4">Metastatic surgery</td><td align="left" rowspan="4">Hospital volume in quartiles (qts) Hospital level</td><td align="left">2nd qt vs 1st qt</td><td align="left">OR (95% CI): 1.14 (0.96&#x02013;1.36)</td></tr><tr><td align="left">3rd qt vs 1st qt</td><td align="left">OR (95% CI): 1.13(0.94&#x02013;1.34)</td></tr><tr><td align="left">4th qt vs 1st qt</td><td align="left">OR (95% CI): 1 (0.82&#x02013;1.23)</td></tr><tr><td align="left">University vs non-university</td><td align="left">OR (95% CI):<bold> 1.94 (1.68&#x02013;2.24)</bold></td></tr><tr><td align="left"/><td align="left">Interaction</td><td align="left" colspan="2">Hospital volume and hospital level</td><td align="left">Wald test p&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left" rowspan="5">Multivariable logistic regression adjusted for both exposures and mediator MDT</td><td align="left" rowspan="5">Metastatic surgery</td><td align="left" rowspan="5">Hospital volume in quartiles (qts) Hospital level mediator MDT</td><td align="left">2nd qt vs 1st qt</td><td align="left">OR (95% CI): 1.13 (0.95&#x02013;1.34)</td></tr><tr><td align="left">3rd qt vs 1st qt</td><td align="left">OR (95% CI): 1.10 (0.92&#x02013;1.32)</td></tr><tr><td align="left">4th qt vs 1st qt</td><td align="left">OR (95% CI): 1 (0.81&#x02013;1.22)</td></tr><tr><td align="left">University vs non-university</td><td align="left">OR (95% CI):<bold> 1.90 (1.64&#x02013;2.19)</bold></td></tr><tr><td align="left">Yes vs no</td><td align="left">OR (95% CI):<bold> 1.54 (1.30&#x02013;1.82)</bold></td></tr><tr><td align="left"/><td align="left">Interaction</td><td align="left" colspan="2">MDT and hospital level</td><td align="left">Wald test p&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left" rowspan="3">Multivariable Cox regression model adjusted</td><td align="left" rowspan="3">All-cause mortality</td><td align="left" rowspan="3">Hospital volume in qts</td><td align="left">2nd qt vs 1st qt</td><td align="left">HR (95% CI): 1.01 (0.95&#x02013;1.07)</td></tr><tr><td align="left">3rd qt vs 1st qt</td><td align="left">HR (95% CI): 1.02 (0.96&#x02013;1.09)</td></tr><tr><td align="left">4th qt vs 1st qt</td><td align="left">HR (95% CI): <bold>0.92 (0.86&#x02013;0.98)</bold></td></tr><tr><td align="left">Multivariable Cox regression model adjusted</td><td align="left">All-cause mortality</td><td align="left">Hospital level</td><td align="left">University vs non-university</td><td align="left">HR (95% CI): <bold>0.85 (0.81&#x02013;0.89)</bold></td></tr><tr><td align="left" rowspan="4">Multivariable Cox regression model adjusted for both exposures</td><td align="left" rowspan="4">All-cause mortality</td><td align="left" rowspan="4">Hospital volume in quartiles (qts) Hospital level</td><td align="left">2nd qt vs 1st qt</td><td align="left">HR (95% CI): 1.04 (0.98&#x02013;1.11)</td></tr><tr><td align="left">3rd qt vs 1st qt</td><td align="left">HR (95% CI): <bold>1.07 (1.00&#x02013;1.14)</bold></td></tr><tr><td align="left">4th qt vs 1st qt</td><td align="left">HR (95% CI): 1.06 (0.98&#x02013;1.14)</td></tr><tr><td align="left">University vs non-university</td><td align="left">HR (95% CI): <bold>0.83 (0.78- 0.88)</bold></td></tr></tbody></table><table-wrap-foot><p>All multivariable models were adjusted for sex (male, female), age (18&#x02013;64,65&#x02013;79,&#x02009;&#x02265;&#x02009;80&#x000a0;years), Charlson comorbidity index (0,1,&#x02009;&#x02265;&#x02009;2), Primary tumour location (right colon, transverse colon, left colon, colon unknown location in colon, rectum), cT-stage (1&#x02013;3, 4, X), cN-stage (0, 1&#x02013;2, X), metastases (single, multiple), civil status (married, not married), education (primary, secondary, higher education), income (4 annual quartiles), diagnosis year (continuous 2009&#x02013;2016). Missing data handled using missing indicator method. Multivariable logistic regression models included 9,966 patients. Multivariable cox regression models included 9,968 patients</p><p>Abbreviations: CI: confidence interval, HR: hazard ratio, MDT: multidisciplinary team conference, OR: odds ratio, qt: quartile</p></table-wrap-foot></table-wrap></p><p id="Par20">The correct Supplementary Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> is given below.</p><p id="Par21">Supplementary Table&#x000a0;3. Summary table of results.
<table-wrap id="Tabd"><table frame="hsides" rules="groups"><thead><tr><th align="left">Analysis</th><th align="left">Outcome</th><th align="left" colspan="2">Exposure</th><th align="left">Results</th></tr></thead><tbody><tr><td align="left" rowspan="3">Multivariable logistic regression adjusted </td><td align="left" rowspan="3">Metastatic surgery</td><td align="left" rowspan="3">Hospital volume in quartiles (qts)</td><td align="left">2nd qt vs 1st qt</td><td align="left">OR (95% CI): <bold>1.23 (1.03&#x02013;1.46)</bold></td></tr><tr><td align="left">3rd qt vs 1st qt</td><td align="left">OR (95% CI): <bold>1.28 (1.08&#x02013;1.52)</bold></td></tr><tr><td align="left">4th qt vs 1st qt</td><td align="left">OR (95% CI): <bold>1.78 (1.52&#x02013;2.09)</bold></td></tr><tr><td align="left">Multivariable logistic regression adjusted</td><td align="left">Metastatic surgery</td><td align="left">Hospital level</td><td align="left">University vs non-university</td><td align="left">OR (95% CI): <bold>1.89 (1.68&#x02013;2.12)</bold></td></tr><tr><td align="left" rowspan="4">Multivariable logistic regression adjusted for both exposures</td><td align="left" rowspan="4">Metastatic surgery</td><td align="left" rowspan="4">Hospital volume in quartiles (qts) Hospital level</td><td align="left">2nd qt vs 1st qt</td><td align="left">OR (95% CI): 1.15 (0.96&#x02013;1.36)</td></tr><tr><td align="left">3rd qt vs 1st qt</td><td align="left">OR (95% CI): 1.14(0.95&#x02013;1.35)</td></tr><tr><td align="left">4th qt vs 1st qt</td><td align="left">OR (95% CI): 1.10 (0.90&#x02013;1.35)</td></tr><tr><td align="left">University vs non-university</td><td align="left">OR (95% CI): <bold>1.86 (1.59&#x02013;2.16)</bold></td></tr><tr><td align="left"/><td align="left">Interaction</td><td align="left" colspan="2">Hospital volume and hospital level</td><td align="left">Wald test p&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left" rowspan="5">Multivariable logistic regression adjusted for both exposures and mediator MDT</td><td align="left" rowspan="5">Metastatic surgery</td><td align="left" rowspan="5">Hospital volume in quartiles (qts) Hospital level mediator MDT</td><td align="left">2nd qt vs 1st qt</td><td align="left">OR (95% CI): 1.13 (0.95&#x02013;1.34)</td></tr><tr><td align="left">3rd qt vs 1st qt</td><td align="left">OR (95% CI): 1.12 (0.94&#x02013;1.33)</td></tr><tr><td align="left">4th qt vs 1st qt</td><td align="left">OR (95% CI): 1.09 (0.89&#x02013;1.33)</td></tr><tr><td align="left">University vs non-university</td><td align="left">OR (95% CI): <bold>1.82 (1.56&#x02013;2.12)</bold></td></tr><tr><td align="left">Yes vs no</td><td align="left">OR (95% CI):<bold> 1.54 (1.30&#x02013;1.82)</bold></td></tr><tr><td align="left"/><td align="left">Interaction</td><td align="left" colspan="2">MDT and hospital level</td><td align="left">Wald test p&#x02009;&#x0003c;&#x02009;0.001</td></tr><tr><td align="left" rowspan="3">Multivariable Cox regression model adjusted</td><td align="left" rowspan="3">All-cause mortality</td><td align="left" rowspan="3">Hospital volume in qts</td><td align="left">2nd qt vs 1st qt</td><td align="left">HR (95% CI): 1.00 (0.94&#x02013;1.07)</td></tr><tr><td align="left">3rd qt vs 1st qt</td><td align="left">HR (95% CI): 1.06 (0.99&#x02013;1.12)</td></tr><tr><td align="left">4th qt vs 1st qt</td><td align="left">HR (95% CI): <bold>0.90 (0.85&#x02013;0.96)</bold></td></tr><tr><td align="left">Multivariable Cox regression model adjusted</td><td align="left">All-cause mortality</td><td align="left">Hospital level</td><td align="left">University vs non-university</td><td align="left">HR (95% CI): <bold>0.85 (0.81&#x02013;0.89)</bold></td></tr><tr><td align="left" rowspan="4">Multivariable Cox regression model adjusted for both exposures</td><td align="left" rowspan="4">All-cause mortality</td><td align="left" rowspan="4">Hospital volume in quartiles (qts) Hospital level</td><td align="left">2nd qt vs 1st qt</td><td align="left">HR (95% CI): 1.02 (0.96&#x02013;1.09)</td></tr><tr><td align="left">3rd qt vs 1st qt</td><td align="left">HR (95% CI): <bold>1.09 (1.02&#x02013;1.16)</bold></td></tr><tr><td align="left">4th qt vs 1st qt</td><td align="left">HR (95% CI): 1.04 (0.96&#x02013;1.12)</td></tr><tr><td align="left">University vs non-university</td><td align="left">HR (95% CI): <bold>0.84 (0.79- 0.89)</bold></td></tr></tbody></table><table-wrap-foot><p>All multivariable models were adjusted for sex (male, female), age (18&#x02013;64,65&#x02013;79,&#x02009;&#x02265;&#x02009;80&#x000a0;years), Charlson comorbidity index (0,1,&#x02009;&#x02265;&#x02009;2), Primary tumour location (right colon, transverse colon, left colon, colon unknown location in colon, rectum), cT-stage (1&#x02013;3, 4, X), cN-stage (0, 1&#x02013;2, X), metastases (single, multiple), civil status (married, not married), education (primary, secondary, higher education), income (4 annual quartiles), diagnosis year (continuous 2009&#x02013;2016). Missing data handled using missing indicator method. Multivariable logistic regression models included 9,966 patients. Multivariable cox regression models included 9,968 patients</p><p>Abbreviations: CI: confidence interval, HR: hazard ratio, MDT: multidisciplinary team conference, OR: odds ratio, qt: quartile</p></table-wrap-foot></table-wrap></p></body><back><ref-list id="Bib1"><title>Reference</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Ljunggren</surname><given-names>M</given-names></name><name><surname>Weibull</surname><given-names>CE</given-names></name><name><surname>Rosander</surname><given-names>E</given-names></name><etal/></person-group><article-title>Hospital factors and metastatic surgery in colorectal cancer patients, a population-based cohort study</article-title><source>BMC Cancer</source><year>2022</year><volume>22</volume><fpage>907</fpage><pub-id pub-id-type="doi">10.1186/s12885-022-10005-8</pub-id><pub-id pub-id-type="pmid">35986249</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Ljunggren M, Weibull CE, Rosander E, et al. Hospital factors and metastatic surgery in colorectal cancer patients, a population-based cohort study. BMC Cancer. 2022;22:907. 10.1186/s12885-022-10005-8.<pub-id pub-id-type="pmid">35986249</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>